Patient’s Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease

Publisher： Karger

E-ISSN： 1421-9867|79|1|30-35

ISSN： 0012-2823

Source： Digestion, Vol.79, Iss.1, 2009-02, pp. : 30-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Physiological Intermolecular Modification Spectroscopy for the Prediction of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 32, Iss. 4, 2014-06 ,pp. : 446-454

Karger

Access to resources Recommend Favorite

Suspected de novo Hepatitis B in a Patient Receiving Anti-Tumor Necrosis Factor Alpha Therapy for the Treatment of Crohn's Disease

By  

Case Reports in Gastroenterology, Vol. 8, Iss. 1, 2014-01 ,pp. : 44-50

Karger

Access to resources Recommend Favorite

The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease

By Kolho Kaija-Leena   Sipponen Taina  

Scandinavian Journal of Gastroenterology, Vol. 49, Iss. 4, 2014-04 ,pp. : 434-441

Informa Healthcare

Access to resources Recommend Favorite

Anti-Tumor Necrosis Factor Nonresponders in Crohn’s Disease: Therapeutic Strategies

By  

Digestive Diseases, Vol. 27, Iss. 3, 2009-09 ,pp. : 351-357

Karger

Access to resources Recommend Favorite

Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease

By  

Digestion, Vol. 88, Iss. 1, 2013-06 ,pp. : 17-19

Karger

Access to resources Recommend Favorite